For 3mg, 7mg, and 14 mg:

Sem-O Tablet is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise:

• As monotherapy when metformin is considered inappropriate due to intolerance or contraindications.
• In combination with other medicinal products for the treatment of diabetes.

For 25mg:

Sem-O (Semaglutide) Tablets are indicated in combination with a reduced calorie diet and increased physical activity:

• To reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition.
• To reduce the risk of major adverse CV events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.
• For the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control.